Start here
Trailer · Why NephSpace
Why I built NephSpace, in my own voice, plus three short moments from the show. Two minutes.
About this trailer
Knowledge, transformed: easy to reach, hard to stop.
New kidney research, picked by a nephrologist: short stories to read, episodes to listen to.
Listen Latest episodes
All episodesDeep Dive · Two Roads: Hemodiafiltration or Medium Cutoff Dialyzers?
Two dialysis patients, same city, same week. One gets a new machine that filters and replaces more than 20 liters every session. The other gets the same old machine with a new filter. Both are told it's the future. Hemodiafiltration has a survival trial but needs new machines. Medium cutoff…
Episode notes, chapters and sourcesWeekly · Oct 2: The Middle-Molecule Race, a Dipstick Adherence Check, and AI for Fellows
Two ways to clear more middle molecules arrive in US dialysis units at once. A urine dipstick can show whether patients are taking their SGLT2 inhibitor. Two papers disagree about who should let AI write the notes. Nine picks from the week of September 21, 2026, each with the story, the numbers…
Episode notes, chapters and sourcesRead Latest stories
All stories
Dialysis
Hemodiafiltration's backers say the US question is now how, not whether
Authors of the main hemodiafiltration trials explain how to prescribe high-volume HDF and predict it will likely become the global standard. Most of them have ties to HDF machine makers.
Dialysis
DaVita moves patients to medium cutoff dialyzers. Its chief medical officer explains why
In a Healio Q&A, Dr. Jeffrey Giullian describes DaVita's switch to medium cutoff dialyzers and why he expects middle-molecule clearance to become standard care. Outcome data are still being gathered.
Glomerular disease
FDA approves obinutuzumab to reduce relapse risk in childhood-onset nephrotic syndrome
The approval covers patients from age 2, including adults whose disease began in childhood. Healio's report rests on a press release and does not yet give the trial's numbers.
CKD and cardiometabolic
Prevention, not just dialysis: an AJKD perspective stakes nephrology's claim in CKM
The authors argue nephrology must move upstream into cardio-kidney-metabolic care, and that the AHA's CKM model undersells the kidney. If nephrologists stay out, CKD will be found more often but diagnosed less precisely.
CKD and cardiometabolic
Most people with CKD die of cardiovascular disease first. A review on catching it
A CJASN review explains why atherosclerosis runs hot in CKD, why chest pain and standard risk scores mislead, which treatments have evidence, plus an inflammation trial that missed.
CKD and cardiometabolic
GLP-1 drugs in CKD: an endocrinologist's guide to starting low and staying on
A CJASN How I Treat case argues the barrier to GLP-1 receptor agonists in CKD is putting them into practice, not the evidence. It lays out titration, lab checks, insulin cuts and how to protect muscle.
CKD and cardiometabolic
Is your patient taking their SGLT2 inhibitor? The urine dipstick may already know
In 45,711 patients newly prescribed an SGLT2 inhibitor, glucose on a routine dipstick went with lower mortality, heart failure hospitalization and kidney failure, while fractures didn't budge. The study is observational, but the check is free.
Other
Start AI with the paperwork, not the prescriptions, a Kidney360 piece argues
Three Mayo Clinic authors map where AI could save time before, during and after a visit. Their first picks are chart summaries, message drafts and admin documents, though the evidence for those uses is still thin.
Other
AI saves the expert time. For a fellow, writing the note may be the lesson
A CJASN trainee perspective sets out what nephrology fellows need to know, do and value in the AI era. It warns of never-skilling: skills that never form because a machine did the work.